Is Coya Therapeutics, Stock a Good Investment?
Coya Therapeutics, Investment Advice | COYA |
- Examine Coya Therapeutics,'s financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Coya Therapeutics,'s leadership team and their track record. Good management can help Coya Therapeutics, navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Coya Therapeutics,'s business and its evolving consumer preferences.
- Compare Coya Therapeutics,'s performance and market position to its competitors. Analyze how Coya Therapeutics, is positioned in terms of product offerings, innovation, and market share.
- Check if Coya Therapeutics, pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Coya Therapeutics,'s stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Coya Therapeutics, Common stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Coya Therapeutics, Common is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Insignificant | Details | |
Volatility | Relatively risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Coya Therapeutics, Stock
Researching Coya Therapeutics,'s stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 20.0% of the company shares are held by institutions such as insurance companies. The book value of Coya Therapeutics, was currently reported as 2.1. The company recorded a loss per share of 0.65. Coya Therapeutics, Common had not issued any dividends in recent years.
To determine if Coya Therapeutics, is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Coya Therapeutics,'s research are outlined below:
| Coya Therapeutics, had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 6 M. Net Loss for the year was (7.99 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Coya Therapeutics, generates negative cash flow from operations | |
| Latest headline from businesswire.com: Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference |
Coya Therapeutics, uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Coya Therapeutics, Common. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Coya Therapeutics,'s previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 3rd of April 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 3rd of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Coya Therapeutics,'s stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Coya Therapeutics,'s investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-12 | 2024-06-30 | -0.14 | -0.19 | -0.05 | 35 | ||
2024-05-08 | 2024-03-31 | -0.29 | -0.35 | -0.06 | 20 | ||
2023-11-08 | 2023-09-30 | -0.37 | -0.48 | -0.11 | 29 | ||
2023-05-10 | 2023-03-31 | -0.43 | -0.28 | 0.15 | 34 | ||
2024-11-06 | 2024-09-30 | -0.415 | -0.26 | 0.155 | 37 |
Coya Therapeutics,'s market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 111.1 M.Market Cap |
|
Coya Therapeutics,'s profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.19) | (0.20) | |
| Return On Capital Employed | (0.22) | (0.23) | |
| Return On Assets | (0.19) | (0.20) | |
| Return On Equity | (0.22) | (0.21) |
Determining Coya Therapeutics,'s profitability involves analyzing its financial statements and using various financial metrics to determine if Coya Therapeutics, is a good buy. For example, gross profit margin measures Coya Therapeutics,'s profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Coya Therapeutics,'s profitability and make more informed investment decisions.
Please note, the presentation of Coya Therapeutics,'s financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Coya Therapeutics,'s management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Coya Therapeutics,'s management manipulating its earnings.
Basic technical analysis of Coya Stock
As of the 29th of November, Coya Therapeutics, shows the Downside Deviation of 6.4, mean deviation of 3.81, and Risk Adjusted Performance of 0.0582. Coya Therapeutics, Common technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Coya Therapeutics,'s insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Coya Therapeutics, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Coya Therapeutics,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Coya Therapeutics, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Understand Coya Therapeutics,'s technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Coya Therapeutics,'s various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0582 | |||
| Market Risk Adjusted Performance | 0.2232 | |||
| Mean Deviation | 3.81 | |||
| Semi Deviation | 5.79 | |||
| Downside Deviation | 6.4 | |||
| Coefficient Of Variation | 1546.43 | |||
| Standard Deviation | 5.88 | |||
| Variance | 34.52 | |||
| Information Ratio | 0.0433 | |||
| Jensen Alpha | 0.1698 | |||
| Total Risk Alpha | (0.51) | |||
| Sortino Ratio | 0.0398 | |||
| Treynor Ratio | 0.2132 | |||
| Maximum Drawdown | 44.12 | |||
| Value At Risk | (7.20) | |||
| Potential Upside | 8.56 | |||
| Downside Variance | 40.92 | |||
| Semi Variance | 33.52 | |||
| Expected Short fall | (4.42) | |||
| Skewness | (1.19) | |||
| Kurtosis | 7.84 |
| Risk Adjusted Performance | 0.0582 | |||
| Market Risk Adjusted Performance | 0.2232 | |||
| Mean Deviation | 3.81 | |||
| Semi Deviation | 5.79 | |||
| Downside Deviation | 6.4 | |||
| Coefficient Of Variation | 1546.43 | |||
| Standard Deviation | 5.88 | |||
| Variance | 34.52 | |||
| Information Ratio | 0.0433 | |||
| Jensen Alpha | 0.1698 | |||
| Total Risk Alpha | (0.51) | |||
| Sortino Ratio | 0.0398 | |||
| Treynor Ratio | 0.2132 | |||
| Maximum Drawdown | 44.12 | |||
| Value At Risk | (7.20) | |||
| Potential Upside | 8.56 | |||
| Downside Variance | 40.92 | |||
| Semi Variance | 33.52 | |||
| Expected Short fall | (4.42) | |||
| Skewness | (1.19) | |||
| Kurtosis | 7.84 |
Consider Coya Therapeutics,'s intraday indicators
Coya Therapeutics, intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Coya Therapeutics, stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Coya Therapeutics, Corporate Filings
| 20th of November 2024 Other Reports | ViewVerify | |
F4 | 14th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 6th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Coya Stock media impact
Far too much social signal, news, headlines, and media speculation about Coya Therapeutics, that are available to investors today. That information is available publicly through Coya media outlets and privately through word of mouth or via Coya internal channels. However, regardless of the origin, that massive amount of Coya data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Coya Therapeutics, news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Coya Therapeutics, relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Coya Therapeutics,'s headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Coya Therapeutics, alpha.
Coya Therapeutics, Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Coya Therapeutics, can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Coya Therapeutics, Corporate Management
| Arun Swaminathan | Chief Officer | Profile | |
| Howard Berman | Executive Chair | Profile | |
| Gregory MacMichael | Chief Officer | Profile | |
| Aaron Thome | Head Platform | Profile | |
| Michelle Frazier | Senior Affairs | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Coya Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Coya Therapeutics,. If investors know Coya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Coya Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.65) | Revenue Per Share 0.687 | Return On Assets (0.29) | Return On Equity (0.51) |
The market value of Coya Therapeutics, Common is measured differently than its book value, which is the value of Coya that is recorded on the company's balance sheet. Investors also form their own opinion of Coya Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Coya Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Coya Therapeutics,'s market value can be influenced by many factors that don't directly affect Coya Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Coya Therapeutics,'s value and its price, as these two are different measures arrived at by various means. Investors typically determine if Coya Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Coya Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.